These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16789742)

  • 1. Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
    Pomel V; Klicic J; Covini D; Church DD; Shaw JP; Roulin K; Burgat-Charvillon F; Valognes D; Camps M; Chabert C; Gillieron C; Françon B; Perrin D; Leroy D; Gretener D; Nichols A; Vitte PA; Carboni S; Rommel C; Schwarz MK; Rückle T
    J Med Chem; 2006 Jun; 49(13):3857-71. PubMed ID: 16789742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphoinositide 3-kinase gamma inhibition plays a crucial role in early steps of inflammation by blocking neutrophil recruitment.
    Ferrandi C; Ardissone V; Ferro P; Rückle T; Zaratin P; Ammannati E; Hauben E; Rommel C; Cirillo R
    J Pharmacol Exp Ther; 2007 Sep; 322(3):923-30. PubMed ID: 17526805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of novel furoquinoline based inhibitors of multiple targets in the PI3K/Akt-mTOR pathway.
    Lohar MV; Mundada R; Bhonde M; Padgaonkar A; Deore V; Yewalkar N; Bhatia D; Rathos M; Joshi K; Vishwakarma RA; Kumar S
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3603-6. PubMed ID: 18501601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors.
    Leahy JW; Buhr CA; Johnson HW; Kim BG; Baik T; Cannoy J; Forsyth TP; Jeong JW; Lee MS; Ma S; Noson K; Wang L; Williams M; Nuss JM; Brooks E; Foster P; Goon L; Heald N; Holst C; Jaeger C; Lam S; Lougheed J; Nguyen L; Plonowski A; Song J; Stout T; Wu X; Yakes MF; Yu P; Zhang W; Lamb P; Raeber O
    J Med Chem; 2012 Jun; 55(11):5467-82. PubMed ID: 22548342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting phosphoinositide 3-kinase gamma to fight inflammation and more.
    Barberis L; Hirsch E
    Thromb Haemost; 2008 Feb; 99(2):279-85. PubMed ID: 18278175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
    Zhu GD; Gandhi VB; Gong J; Thomas S; Woods KW; Song X; Li T; Diebold RB; Luo Y; Liu X; Guan R; Klinghofer V; Johnson EF; Bouska J; Olson A; Marsh KC; Stoll VS; Mamo M; Polakowski J; Campbell TJ; Martin RL; Gintant GA; Penning TD; Li Q; Rosenberg SH; Giranda VL
    J Med Chem; 2007 Jun; 50(13):2990-3003. PubMed ID: 17523610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3Kgamma differentially regulates FcepsilonRI-mediated degranulation and migration of mast cells by and toward antigen.
    Endo D; Gon Y; Nunomura S; Yamashita K; Hashimoto S; Ra C
    Int Arch Allergy Immunol; 2009; 149 Suppl 1():66-72. PubMed ID: 19494508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol as an isozyme-selective inhibitor of PI3K for the treatment of ischemia reperfusion injury associated with myocardial infarction.
    Palanki MS; Dneprovskaia E; Doukas J; Fine RM; Hood J; Kang X; Lohse D; Martin M; Noronha G; Soll RM; Wrasidlo W; Yee S; Zhu H
    J Med Chem; 2007 Sep; 50(18):4279-94. PubMed ID: 17685602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis for isoform selectivity in a class of benzothiazole inhibitors of phosphoinositide 3-kinase γ.
    Collier PN; Martinez-Botella G; Cornebise M; Cottrell KM; Doran JD; Griffith JP; Mahajan S; Maltais F; Moody CS; Huck EP; Wang T; Aronov AM
    J Med Chem; 2015 Jan; 58(1):517-21. PubMed ID: 24754609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.
    Billottet C; Banerjee L; Vanhaesebroeck B; Khwaja A
    Cancer Res; 2009 Feb; 69(3):1027-36. PubMed ID: 19176369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3Kβ inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancers.
    Certal V; Halley F; Virone-Oddos A; Delorme C; Karlsson A; Rak A; Thompson F; Filoche-Rommé B; El-Ahmad Y; Carry JC; Abecassis PY; Lejeune P; Vincent L; Bonnevaux H; Nicolas JP; Bertrand T; Marquette JP; Michot N; Benard T; Below P; Vade I; Chatreaux F; Lebourg G; Pilorge F; Angouillant-Boniface O; Louboutin A; Lengauer C; Schio L
    J Med Chem; 2012 May; 55(10):4788-805. PubMed ID: 22524426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overlapping and distinct roles for PI3Kbeta and gamma isoforms in S1P-induced migration of human and mouse endothelial cells.
    Heller R; Chang Q; Ehrlich G; Hsieh SN; Schoenwaelder SM; Kuhlencordt PJ; Preissner KT; Hirsch E; Wetzker R
    Cardiovasc Res; 2008 Oct; 80(1):96-105. PubMed ID: 18558630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Action mechanisms and structure-activity relationships of PI3Kgamma inhibitors on the enzyme: a molecular modeling study.
    Kuang RR; Qian F; Li Z; Wei DZ; Tang Y
    Eur J Med Chem; 2006 Apr; 41(4):558-65. PubMed ID: 16545498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and structure-activity relationships of ring-opened 17-hydroxywortmannins: potent phosphoinositide 3-kinase inhibitors with improved properties and anticancer efficacy.
    Zask A; Kaplan J; Toral-Barza L; Hollander I; Young M; Tischler M; Gaydos C; Cinque M; Lucas J; Yu K
    J Med Chem; 2008 Mar; 51(5):1319-23. PubMed ID: 18269228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The identification of potent, selective and CNS penetrant furan-based inhibitors of B-Raf kinase.
    Takle AK; Bamford MJ; Davies S; Davis RP; Dean DK; Gaiba A; Irving EA; King FD; Naylor A; Parr CA; Ray AM; Reith AD; Smith BB; Staton PC; Steadman JG; Stean TO; Wilson DM
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4373-6. PubMed ID: 18621524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphoinositide 3-kinase gamma (PI3Kgamma) inhibitors for the treatment of inflammation and autoimmune disease.
    Venable JD; Ameriks MK; Blevitt JM; Thurmond RL; Fung-Leung WP
    Recent Pat Inflamm Allergy Drug Discov; 2010 Jan; 4(1):1-15. PubMed ID: 20017720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PI3Kgamma is a key regulator of inflammatory responses and cardiovascular homeostasis.
    Hawkins PT; Stephens LR
    Science; 2007 Oct; 318(5847):64-6. PubMed ID: 17916723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus.
    Barber DF; Bartolomé A; Hernandez C; Flores JM; Redondo C; Fernandez-Arias C; Camps M; Rückle T; Schwarz MK; Rodríguez S; Martinez-A C; Balomenos D; Rommel C; Carrera AC
    Nat Med; 2005 Sep; 11(9):933-5. PubMed ID: 16127435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationships and molecular modelling of 5-arylidene-2,4-thiazolidinediones active as aldose reductase inhibitors.
    Maccari R; Ottanà R; Curinga C; Vigorita MG; Rakowitz D; Steindl T; Langer T
    Bioorg Med Chem; 2005 Apr; 13(8):2809-23. PubMed ID: 15781392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis.
    Camps M; Rückle T; Ji H; Ardissone V; Rintelen F; Shaw J; Ferrandi C; Chabert C; Gillieron C; Françon B; Martin T; Gretener D; Perrin D; Leroy D; Vitte PA; Hirsch E; Wymann MP; Cirillo R; Schwarz MK; Rommel C
    Nat Med; 2005 Sep; 11(9):936-43. PubMed ID: 16127437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.